2213155
Project Grant
Overview
Grant Description
Sbir Phase I: An Extravascular Bipolar Catheter for Targeted Nerve Ablation with Minimal Collateral Damage to Surrounding Tissues -The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is a novel and emerging method for treating a subset of heart failure patients. Despite modern medical regimen and device therapies, heart failure affects 6 million Americans and remains a leading cause of death and hospitalization in the United States.
The proposed system and approach aim to provide a novel procedure and treatment paradigm by leveraging an established clinical access procedure for performing Greater Splanchic Ablation (GSN). The system would enable rapid and wider clinical adoption of the emerging therapy.
This Small Business Innovation Research Phase I project will develop a novel, minimally invasive, catheter-delivered, venous procedure for performing extravascular Greater Splanchic Ablation (GSN). The proposed catheter system utilizes a clinically accepted venous approach in order to perform extravascular denervation, while minimizing collateral (off-target) damage to the other surrounding tissues.
The objectives of this project include designing and prototyping new devices that will enable localized energy delivery and incorporate a detection system indicative of procedural success. Both benchtop testing and pre-clinical animal model studies will be used to access and ablate, verifying the function and performance of the device.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
The proposed system and approach aim to provide a novel procedure and treatment paradigm by leveraging an established clinical access procedure for performing Greater Splanchic Ablation (GSN). The system would enable rapid and wider clinical adoption of the emerging therapy.
This Small Business Innovation Research Phase I project will develop a novel, minimally invasive, catheter-delivered, venous procedure for performing extravascular Greater Splanchic Ablation (GSN). The proposed catheter system utilizes a clinically accepted venous approach in order to perform extravascular denervation, while minimizing collateral (off-target) damage to the other surrounding tissues.
The objectives of this project include designing and prototyping new devices that will enable localized energy delivery and incorporate a detection system indicative of procedural success. Both benchtop testing and pre-clinical animal model studies will be used to access and ablate, verifying the function and performance of the device.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Awardee
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Cordova,
Tennessee
38016-4563
United States
Geographic Scope
Single Zip Code
Related Opportunity
None
Corveus Medical was awarded
Project Grant 2213155
worth $255,841
from National Science Foundation in March 2023 with work to be completed primarily in Cordova Tennessee United States.
The grant
has a duration of 1 year and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
SBIR Details
Research Type
SBIR Phase I
Title
SBIR Phase I:An extravascular bipolar catheter for targeted nerve ablation with minimal collateral damage to surrounding tissues
Abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is a novel and emerging method for treating a subset of heart failure patients. Despite modern medical regimen and device therapies, heart failure affects 6 million Americans and remains a leading cause of death and hospitalization in the United States. The proposed system and approach aim to provide a novel procedure and treatment paradigm by leveraging an established clinical access procedure for performing Greater Splanchnic Ablation (GSN). The system would enable rapid and wider clinical adoption of the emerging therapy._x000D_ _x000D_ This Small Business Innovation Research Phase I project will develop a novel, minimally invasive, catheter-delivered, venous procedure for performing extravascular Greater Splanchnic Ablation (GSN). The proposed catheter system utilizes a clinically accepted venous approach in order to perform extravascular denervation, while minimizing collateral (off-target) damage to the other surrounding tissues. The objectives of this project include designing and prototyping new devices that will enable localized energy delivery and incorporate a detection system indicative of procedural success. Both benchtop testing and pre-clinical animal model studies will be used to access and ablate, verifying the function and performance of the device._x000D_ _x000D_ This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
MD
Solicitation Number
NSF 21-562
Status
(Complete)
Last Modified 3/2/23
Period of Performance
3/1/23
Start Date
2/29/24
End Date
Funding Split
$255.8K
Federal Obligation
$0.0
Non-Federal Obligation
$255.8K
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
2213155
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
GFC9AFW64C11
Awardee CAGE
946B0
Performance District
Not Applicable
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| Research and Related Activities, National Science Foundation (049-0100) | General science and basic research | Grants, subsidies, and contributions (41.0) | $255,841 | 100% |
Modified: 3/2/23